Iranian Firm Produces New Drug for Treatment of Breast, Gastrointestinal Cancer
“This drug has created a major revolution in cancer treatment and is produced by using the conjugate drug method,” said Ali Aqajani, the business development manager of the knowledge-based company.
He explained that in this complex technology, antibodies as carriers deliver cancer cell-killing drugs precisely to the target, adding, “This method significantly increases the effectiveness of treatment compared to conventional drugs, while reducing side effects.”
“This drug significantly increases the lifespan of patients by delaying the recurrence of the disease and worsening of their condition by 6 times, and this achievement is considered an important development in the field of cancer treatment on a global level,” he said, noting that the drug is at present in full production and is ready to enter the third phase of clinical studies after receiving the code of ethics.
In a relevant development in September, a research team of an Iranian knowledge-based company stationed at Pardis Science and Technology Park near Tehran had also succeeded in producing an engineered oncolytic virus for the treatment of glioblastoma cancer.
The main focus of the company is on the design and manipulation of vectors and viruses. By providing advanced GLP and GMP infrastructure and the presence of a team of experienced researchers, the complex is able to complete the full cycle of biological and biotechnological product production from zero to one hundred; from proposal and vector design to vector production, conducting cellular and animal experiments, and finally making the final product.
“Our product has been manufactured in three series and all of its preclinical stages have been completed. We are currently compiling documentation to obtain approval from the Food and Drug Administration of Iran and will soon enter the clinical phases,” said Massoumeh Alamdar, the production manager and a research team member of the knowledge-based company.
“Our product is used to treat glioblastoma cancer. It is actually an engineered oncolytic virus that, through genetic changes and manipulations, has been transformed into a form that enjoys the capability to target and destroy cancer cells. The technical and research stages of this product have been completed and we are now preparing its documentation,” she added.
4155/v
